Collectively, these findings signify the multifaceted impact of GLP-1 agonists on gut microbiota composition and metabolic health, offering promising ways for the development of targeted therapeutic interventions for obesity and related metabolic disorders. Here, GCG is linked to obesity due to melanocortin 4 receptor deficiency.